Concord Drugs (BOM:538965) Long-Term Debt: ₹0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
64 GF Score
Price ₹81.92
GF Value ₹64.35
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Concord Drugs Long-Term Debt?

Concord Drugs BOM:538965 +1.61% 64 Long-Term Debt is ₹0.0 Mil as of Jun. 2026. GuruFocus rates BOM:538965 with a GF Score™ of 64/100 and a GF Value™ of ₹64.35 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Concord Drugs's Long-Term Debt for the quarter that ended in Jun. 2026 was ₹0.0 Mil.

Concord Drugs's quarterly Long-Term Debt increased from Dec. 2025 (₹0.0 Mil) to Mar. 2026 (₹18.1 Mil) but then declined from Mar. 2026 (₹18.1 Mil) to Jun. 2026 (₹0.0 Mil).

Concord Drugs's annual Long-Term Debt increased from Mar. 2024 (₹6.5 Mil) to Mar. 2025 (₹13.2 Mil) and increased from Mar. 2025 (₹13.2 Mil) to Mar. 2026 (₹18.1 Mil).

Concord Drugs  (BOM:538965) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Concord Drugs Long-Term Debt Related Terms

Concord Drugs Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Concord Drugs's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs Long-Term Debt Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.95 19.11 6.45 13.24 18.06

Concord Drugs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 9.87 0.00 18.06 0.00
BOM:538965
64GF Score
Concord Drugs Ltd BOM:538965
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0.0 Mil mean?
Concord Drugs (BOM:538965) has a Long-Term Debt of ₹0.0 Mil as of Jun. 2026.
Is Concord Drugs' Long-Term Debt too high?
Concord Drugs' current Long-Term Debt is ₹0.0 Mil. Overall, Concord Drugs has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Long-Term Debt compare to ZTS?
Concord Drugs' Long-Term Debt of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Concord Drugs's current Long-Term Debt is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹64.35, compared to a current price of ₹81.92 — trading 27.3% above its estimated fair value. The current Long-Term Debt is ₹0.0 Mil. Concord Drugs' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Long-Term Debt is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹81.92 is trading 27.3% above its estimated GF Value™ of ₹64.35. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Long-Term Debt: ₹0.0 Mil
  • GF Value™: ₹64.35 vs. price of ₹81.92 (27.3% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
64GF Score

Get the complete analysis for BOM:538965

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹81.92
Price
₹64.35
GF Value